ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. | After winning a broader FDA label in metastatic castration-resistant prostate cancer, Pfizer’s combination of Talzenna and Xtandi is claiming a phase 3 win that positions it for a wider castration-sensitive patient population compared with J&J’s PARP doublet Akeega.